Trevi Therapeutics Stock (NASDAQ:TRVI), Trade Ideas

Trevi Therapeutics

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ALLR

ANGN

AXLA

BBBY

BLBX

BLCM

CFRX

CJJD

CLSK

CNSP

CYTO

DBGI

DRMA

ERIC

EVAX

GMDA

GSMG

HTGM

KRBP

LIDR

MRUS

NOTE

OBLG

PEAR

PHIO

PRST

PTPI

RIOT

RLAY

SABS

SBSW

SDIG

SLGG

TORO

Tempest Therapeutics, Inc. - Common Stock

TPST

TRVI

UIHC

WINT

Gainers


	Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional investors at $2.48 per share.


Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

ADSK

AGBA

COMS

Core Scientific, Inc. - Class A Common Stock

CORZ

COSM

FOXO

GSUN

KSPN

MANU

MSGM

NMTC

OBSV

OPGN

PAGS

PALI

VERO

Gainers


	COMSovereign Holding Corp. (NASDAQ: COMS) shares rose 58.4% to $0.1069 in pre-market trading after gaining more than 16% on Tuesday.


Why Manchester United Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

AMPX

AMRS

ANVS

APGN

ARAV

ARQQ

BCAN

BLUE

BTCS

CGNX

CHNG

CIFR

CLEU

CLVS

CRKN

DWAC

EDRY

GMBL

GROV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HYRE

IMTE

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

MCLD

MEDS

MGAM

MTEX

MYNA

NRBO

NRIX

OIIM

PBTS

PETV

QBTS

RCOR

REBN

REFR

RKLY

SAVA

SOBR

SPPI

SVRE

SWVL

TELL

TRKA

VALU

VERY

VIRI

VRAX

VTAQ

WEAV

Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday

Trevi Therapeutics Inc

Barclays analyst Eric Beaumont maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a Overweight and raises the price target from $20 to $21.

Price Target

Analyst Ratings

Barclays Maintains Overweight on PG&E, Raises Price Target to $21

Wedbush analyst David Chiaverini maintains First Foundation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NYSE">FFWM</a>) with a Neutral and lowers the price target from $8 to $7.

FFWM

Wedbush Maintains Neutral on First Foundation, Lowers Price Target to $7

Centene Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) reported&nbsp;first-quarter&nbsp;sales of&nbsp;$40.41 billion, up&nbsp;11%&nbsp;Y/Y, beating the consensus of&nbsp;$36.14 billion.
Premium and service revenues increased 4% to&nbsp;$36.3 billion, driven by membership growth in the Marketplace business due to strong product positioning and overall market growth, partially offset by recent divestitures in the Other segment and lower Medicaid membership primarily&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38454080/centene-corporation-reports-first-quarter-2024-results" rel="noreferrer noopener">due to redeterminations</a>.
The health benefits ratio of 87.1% for the first quarter of 2024 represented an increase from 87.0% in the comparable period in 2023.
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38255526/see-how-floridas-much-awaited-medicaid-re-procurement-awards-impact-centene-humana-" rel="noreferrer noopener">See How Florida&#8217;s Much Awaited Medicaid Re-Procurement Awards Impact Centene, Humana, Molina</a>.
The company reported a&nbsp;first-quarter&nbsp;adjusted EPS of $2.26, up from $2.11 a year ago, beating the consensus of $2.08.
&#8220;Centene&#8217;s first quarter results demonstrate the strength of our diversified platform,&#8221; Centene CEO Sarah London said in a statement accompanying the company&#8217;s earnings report. &#8220;We are pleased to raise full-year 2024 guidance as we look to maximize the positive momentum being generated by our core businesses.&#8221;
Centene said total managed care membership held steady at 28.42 million at the end of the first quarter of this year, compared to 28.45 million a year ago.
Centene&#8217;s enrollment in its &#8220;commercial marketplace&#8221; business grew to 4.3 million members from 3 million a year ago.&nbsp;
Premium revenues from Commercial business increased 48% Y/Y to&nbsp;$7.8 billion.
Total Medicaid memberships fell over 18% to 13.3 million from 16.3 million.
Guidance:&nbsp;Centene revised its 2024 adjusted EPS&nbsp;guidance&nbsp;floor of greater than&nbsp;$6.80&nbsp;versus prior&nbsp;guidance&nbsp;of greater than&nbsp;$6.70&nbsp;versus consensus of&nbsp;$6.78.
Centene expected 2024 revenue guidance of $147.5 billion-$150.5 billion versus the consensus Of&nbsp;$146.14 billion, including premium and service revenues of&nbsp;$135.5 billion-$138.5 billion&nbsp;versus prior guidance of $134.5 billion-$137.5 billion.
CNC Price Action:&nbsp;Centine shares are down 4.11%&nbsp;at&nbsp;$72.57&nbsp;at publication Friday.
Read Next: <a href="https://www.benzinga.com/general/macro-notification/24/04/38458581/feds-key-inflation-indicator-hits-2-8-dashes-rate-cut-hopes-traders-on-alert">Fed&#8217;s Key Inflation Indicator Hits 2.8%, Dashes Rate Cut Hopes; Traders On Alert</a>
Photo: Shutterstock

Earnings

Guidance

Health Care

General

Centene's First-Quarter Surge: Sales Soar To $40.41B, Exceeding Expectations: What's Next For The Healthcare Company?

<a href="https://www.theverge.com/2024/4/26/24141361/tesla-autopilot-fsd-nhtsa-investigation-report-crash-death" title="https://www.theverge.com/2024/4/26/24141361/tesla-autopilot-fsd-nhtsa-investigation-report-crash-death">https://www.theverge.com/2024/4/26/24141361/tesla-autopilot-fsd-nhtsa-investigation-report-crash-death</a>

TSLA

'Tesla's Autopilot And Full Self-Driving Linked To Hundreds Of Crashes, Dozens Of Deaths' - The Verge

Barclays analyst Raimo Lenschow maintains Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Equal-Weight and raises the price target from $66 to $69.

PEGA

Barclays Maintains Equal-Weight on Pegasystems, Raises Price Target to $69

Piper Sandler analyst Scott Siefers maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Neutral and raises the price target from $20 to $21.

Piper Sandler Maintains Neutral on Regions Finl, Raises Price Target to $21

In a recent social media update, a well-known crypto analyst, Crypto Dog, forecasted a bullish run for memecoin Jeo Boden (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BODEN</a>) and NEAR Protocol (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/near/usd">NEAR</a>).
What Happened: Crypto Dog anticipates that BODEN is on the verge of a breakout following a consolidation period, Daily Hodl<a href="https://dailyhodl.com/2024/04/26/trader-says-memecoin-thats-exploded-over-2400-in-weeks-about-to-go-higher-updates-outlook-on-near-protocol/"> reported</a> on Thursday. The memecoin has witnessed a remarkable twenty-fold surge since the beginning of March.
The analyst&#8217;s chart indicates that BODEN is currently testing a downward-sloping resistance level on its daily chart. 
Crypto Dog also highlighted that several other memecoins, including dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>), are showing bullish signs. 
&#8220;Not just WIF though, a good handful of mid/high cap memecoins are aiming for new highs,&#8221; he stated.
Regarding NEAR Protocol, Crypto Dog expressed a bullish sentiment based on the artificial intelligence (AI) narrative, among other factors. NEAR&#8217;s Co-Founder Illia Polosukhin had previously stated that AI would be &#8220;one of the core verticals for the NEAR ecosystem heading into 2024&#8221;. 
The analyst concluded, &#8220;&#8230;still think NEAR will lead over the next weeks, months. Structurally it looks great, erased recent dip outperforming Bitcoin and even Solana.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38407752/bitcoin-veteran-warns-crypto-bears-you-have-no-idea-how-crazy-this-bull-run-is-about-to-be?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Veteran Warns Crypto Bears: &#8216;You Have No Idea How Crazy This Bull Run Is About To Be&#8217;</a>
Why It Matters: Memecoin BODEN, a parody of President Joe Biden, has been on a bullish run, recording a new all-time high and<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38152348/jeo-boden-meme-coin-up-more-than-21-spikes-past-1-imagine-when-trump-starts-saying-boden-m"> crossing the $700 million market capitalization mark </a>in early April. The coin attracted attention from supporters of both political parties, with a Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) influencer predicting that it would gain traction due to Biden&#8217;s slow pace.
Just days after its launch, an anonymous trader turned <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38184775/a-trader-turns-356k-into-5-8m-with-biden-related-jeo-boden-meme-coin">a $356K investment in BODEN into $5.8M.</a> This indicates the potential profitability of investing in meme coins.
Despite many meme coins surpassing the $1 billion market cap milestone, <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38428112/only-dogecoin-and-shiba-inu-have-crossed-the-10b-meme-coin-mark-who-will-be-the-third-muse">only two have crossed the $10 billion threshold</a>. 
Meanwhile, Strike CEO Jack Mallers has forecasted a potential seven-figure price for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) during the current cycle, driven by efforts to save the bond market.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38386424/shiba-inu-whale-accumulates-237b-shib-in-one-transaction-much-in-store-for-the-shib-army-v?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shiba Inu Whale Accumulates 237B SHIB In One Transaction: &#8216;Much In Store For The SHIB Army,&#8217; Vows Lead Developer</a>
Photo via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BODEN

$BTC

$NEAR

$SOL

$WIF

Biden-Inspired 'Jeo Boden,' Dogwifhat And Other Memecoins 'Are Aiming For New Highs,' Says Crypto Analyst

Wedbush analyst David Chiaverini maintains Customers Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBI#NYSE">CUBI</a>) with a Outperform and lowers the price target from $63 to $61.

CUBI

Wedbush Maintains Outperform on Customers Bancorp, Lowers Price Target to $61

Barclays analyst Benjamin Budish maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Overweight and lowers the price target from $76 to $73.

NDAQ

Barclays Maintains Overweight on Nasdaq, Lowers Price Target to $73

Piper Sandler analyst Scott Siefers maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Neutral and raises the price target from $54 to $56.

Piper Sandler Maintains Neutral on Comerica, Raises Price Target to $56

Piper Sandler analyst Scott Siefers upgrades Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) from Neutral to Overweight and raises the price target from $35 to $41.

Upgrades

Piper Sandler Upgrades Citizens Financial Group to Overweight, Raises Price Target to $41

WIIM

KLAC

KLA Corporation shares are trading higher after the company reported better-than-expected Q3 financial results and issued guidance.

Ginkgo Bioworks Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) short percent of float has risen 3.26% since its last report. The company recently reported that it has 270.83 million shares sold short, which is 19.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 16.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ginkgo Bioworks Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714140922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ginkgo Bioworks Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ginkgo Bioworks Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ginkgo Bioworks Holdings's peer group average for short interest as a percentage of float is 3.35%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Ginkgo Bioworks Holdings's Recent Short Interest

D.R. Horton's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) short percent of float has risen 6.78% since its last report. The company recently reported that it has 4.99 million shares sold short, which is 1.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>D.R. Horton Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714140917_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for D.R. Horton has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing D.R. Horton's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, D.R. Horton's peer group average for short interest as a percentage of float is 6.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into D.R. Horton's Recent Short Interest

Amphenol's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) short percent of float has risen 5.84% since its last report. The company recently reported that it has 7.60 million shares sold short, which is 1.45% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Amphenol Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714140912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amphenol has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Amphenol's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Amphenol's peer group average for short interest as a percentage of float is 4.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Amphenol's Recent Short Interest

Susquehanna analyst Bascome Majors maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Neutral and raises the price target from $255 to $270.

Susquehanna Maintains Neutral on Union Pacific, Raises Price Target to $270

Barclays analyst Stephanie Davis maintains Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and lowers the price target from $234 to $213.

Laboratory Corporation Of America Holdings

Barclays Maintains Equal-Weight on Laboratory Corp, Lowers Price Target to $213

Wedbush analyst David Chiaverini reiterates Cullen/Frost Bankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>) with a Neutral and maintains $115 price target.

Reiteration

Wedbush Reiterates Neutral on Cullen/Frost Bankers, Maintains $115 Price Target

Susquehanna analyst Charles Minervino maintains Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) with a Positive and lowers the price target from $110 to $105.

Susquehanna Maintains Positive on Textron, Lowers Price Target to $105

Former President Donald Trump was ordered to pay <a href="https://www.benzinga.com/news/24/02/37382129/trumps-appeal-against-450m-judgment-collection-rejected-by-ny-judge-former-presidents-properties-at">$355 million in penalties</a> for fraud charges and profits on the sale of different assets.&nbsp;
The penalties have been accumulating interest at a rate of 9% per year and have snowballed to current liabilities above $450 million. The fine is growing at a rate of <a href="https://www.benzinga.com/news/24/02/37235445/donald-trumps-unpaid-355m-fine-accumulates-2-6m-in-interest-every-month-judge-rules">$2.6 million per month</a>. The penalties have put Trump at risk of the court seizing his assets.&nbsp;
With a costly presidential campaign and high levels of financial scrutiny, Trump's ability to repay the fine is questionable, and many wonder whether he will be able to pay it back at all.&nbsp;
Don't Miss:
<ul>
<li>If you invested $100 in DOGE when Elon Musk first tweeted about it in 2019,<a href="https://www.benzinga.com/money/etoro-doge"> here&#8217;s how much you&#8217;d have today</a>.</li>
<li>Bitcoin has jumped another 45% already this year &#8211;<a href="https://www.benzinga.com/money/kraken"> how much would you need to get started today?</a></li>
</ul>
But Trump's crypto holdings are not often considered in this ordeal. While the holdings are just a drop in the bucket compared to the amount owed, the potential price appreciation could help Trump pay the penalties.
Trump's crypto portfolio was discovered by Arkham Intelligence, which cross-referenced Trump's financial disclosures with transactions on the blockchain to find his <a href="https://platform.arkhamintelligence.com/explorer/entity/donald-trump">wallet address</a>.&nbsp;
The wallet holds several million dollars in cryptocurrency, most of which is between three different tokens: Ethereum (ETH) Wrapped Ethereum (WETH) and MAGA Coin (TRUMP).
The ETH and WETH were obtained through the Trump Digital Trading Cards non-fungible token (NFT) project. Though Trump was not affiliated with the project, the creators gave him royalties exceeding 1,700 ETH. In December, <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/37185916/donald-trump-sold-2-4-million-in-eth-last-month-missed-out-on-500-000-in-potential-profit">Trump sold 1,075 of these ETH tokens</a>, which generated proceeds of $2.4 million.&nbsp;
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Large boom in cryptocurrency and metaverse interest as BTC skyrockets —<a href="https://www.benzinga.com/money/ceek"> has Apple Vision Pro increased the demand for virtual real estate?</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Regarding potential growth, the roughly 700 ETH Trump has remaining could be worth as much as $7 million by the end of 2025, based on a <a href="https://www.benzinga.com/money/ethereum-eth-price-predictions">price prediction</a> of $10,000. Trump could also continue to receive cash from NFT projects and royalties in the future.
While ETH could see growth in the coming months and years, Trump could generate much more profit from MAGA Coin (TRUMP). The creators of this token sent Trump 580,000 tokens when the project launched in August. At the time, the tokens were worth a few thousand dollars, but they have since appreciated to over $3 million.&nbsp;
The token could continue to grow if Trump wins the election in November or if he directly endorses the project. Other meme coins, such as dogwifhat (WIF) and Bonk (BONK) have attracted investment to the order of several billion dollars. So, if MAGA Coin were to reach a market cap of $3 billion, similar to WIF, the price would be around $70, and Trump's position would be worth over $40 million.&nbsp;
This is unlikely to happen, as a $3 billion market cap is far from the current level of around $250 million, and numerous events would have to play out for the token to get there.&nbsp;
With that in mind, Trump's crypto dealings have a small chance of providing relief to his financial situation. Because the portfolio is public, anyone can monitor his positions and how much he has in crypto.&nbsp;
Read Next:
<ul>
<li>About 22% of the adult population in the U.S. own a share of Bitcoin,<a href="https://www.benzinga.com/money/kraken"> how much would $10 get you today</a>?</li>
<li>The<a href="https://www.benzinga.com/money/kraken-2"> last-standing top crypto exchange without a major security breach</a> offers what now?</li>
</ul>

Donald Trump's Crypto Investments Could Help Pay Back His $450M In Damages

Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Trevi Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/trvi-stock-quote/">TRVI</a>) just reported results for the fourth quarter of 2023.<ul><li>Trevi Therapeutics reported earnings per share of -8 cents. This was above the analyst estimate for EPS of -9 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/trvi-stock-earnings-trevi-therapeutics-for-q4-of-2023/">TRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trevi Therapeutics (TRVI – Research Report) and Walg...

Analysts' Top Healthcare Picks: Trevi Therapeutics (TRVI), Walgreens Boots Alliance (WBA)

Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) today and set a price target of $8.00...

Trevi Therapeutics (TRVI) Receives a Buy from Stifel Nicolaus

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vor Biopharma (VOR – Research Report), Roche Holdi...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (VOR), Roche Holding AG (OtherRHHVF) and Trevi Therapeutics (TRVI)

Trevi Therapeutics (TRVI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani fr...

Buy Rating for Trevi Therapeutics Anchored on Haduvio's Clinical Promise and Market Potential